# US 2021/0171636 A1 · Inhibition of cytokine-induced sh2 protein in nk cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171636 A1
- Document ID: US20210171636A1
- Status: Published application
- Kind: A1
- Application number: 17/115,896
- Filed: 2020-12-09
- Published: 2021-06-10
- Earliest claimed: 2015-12-16
- Assignees: The Walter and Eliza Hall Institute of Medical Research
- Applicants: The Walter and Eliza Hall Institute of Medical Research
- Inventors: Nicholas D. Huntington; Sandra E. Nicholson; Jeff Babon; Tatiana Kolesnik
- Web page: https://patentgrep.com/patent/US20210171636A1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/04: Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof ({enzyme inhibitors A61K38/005;} gastrins {A61K38/2207}, somatostatins A61K38/31, melanotropins A61K38/34 {; protease inhibitors A61K38/55})
- A61K 38/1709: {from mammals}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/18: against material from animals or humans
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/46: characterised by the cancer treated
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2239/49: Breast
- A61K 2239/55: Lung
- A61K 2239/57: Skin; melanoma
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition

## Claims

### Claim at position 1

1-64. (canceled)

### Claim 65

A method for adoptive cell therapy or prophylaxis comprising administering CIS-inhibited NK cells or CIS-inhibited T cells to a subject suffering from or determined to be at risk of suffering from a cancer or an infection.

### Claim 66 (depends on 65)

The method of claim 65, comprising administering CIS-inhibited NK cells.

### Claim 67 (depends on 65)

The method of claim 65, comprising administering CIS-inhibited T cells.

### Claim 68 (depends on 65)

The method of claim 65, wherein the CIS-inhibited NK cells or CIS-inhibited T cells are NK cells or T cells contacted ex vivo with a CIS inhibitor, or genetically modified ex vivo to have reduced expression of CIS.

### Claim 69 (depends on 68)

The method of claim 68, wherein the CIS-inhibited NK cells or CIS-inhibited T cells are NK cells or T cells genetically modified to have reduced expression of CIS.

### Claim 70 (depends on 69)

The method of claim 69, wherein the CIS-inhibited NK cells or CIS-inhibited T cells are Cish−/−.

### Claim 71 (depends on 68)

The method of claim 68, wherein the CIS-inhibited NK cells or the CIS-inhibited T cells are NK cells or T cells contacted ex vivo with a CIS inhibitor.

### Claim 72 (depends on 71)

The method of claim 71, wherein the CIS inhibitor is a peptide, a peptidomimetic, a small molecule, a polynucleotide, or a polypeptide.

### Claim 73 (depends on 72)

The method of claim 72, wherein the peptide is a phosphopeptide or a phosphomimetic peptide.

### Claim 74 (depends on 72)

The method of claim 72, wherein the polynucleotide is a dsRNA.

### Claim 75 (depends on 72)

The method of claim 72, wherein the polynucleotide encodes a dominant-negative inhibitor of CIS.

### Claim 76 (depends on 71)

The method of claim 71, wherein the CIS inhibitor competitively inhibits binding of CIS to JAK1 and/or JAK3.

### Claim 77 (depends on 76)

The method of claim 76, wherein JAK1 is phosphorylated JAK1 and/or JAK3 is phosphorylated JAK3.

### Claim 78 (depends on 77)

The method of claim 77, wherein phosphorylated JAK1 is phosphorylated at Tyr1034 and/or phosphorylated JAK3 is phosphorylated at Tyr980.

### Claim 79 (depends on 71)

The method of claim 71, wherein the CIS inhibitor competitively inhibits binding of CIS to IL-2Rβ phosphorylated at one or more of Tyr355, Tyr361 and Tyr392 and/or competitively inhibits binding of CIS to one or more of Elongin B, Elongin C or Cullin-5.

### Claim 80 (depends on 65)

The method of claim 65, further comprising administering one or more of IL-15, an IL-15 agonist, a B Raf protein kinase inhibitor, a MEK protein kinase inhibitor, or an immunotherapeutic agent, to the subject.

### Claim 81 (depends on 65)

The method of claim 65, wherein the subject is suffering from a cancer, or is determined to be at risk of suffering from a cancer.

### Claim 82 (depends on 81)

The method of claim 81, wherein the cancer comprises a tumour.

### Claim 83 (depends on 81)

The method of claim 81, wherein the cancer is selected from the group consisting of: metastatic melanoma, metastatic prostate cancer, metastatic breast cancer, triple negative breast cancer, bladder cancer, brain cancer, esophageal cancer, liver cancer, head and neck cancer, squamous cell lung cancer, non-small lung cell cancer, Merkel cell carcinoma, sarcoma, hepatocellular cancer, multiple myeloma, pancreatic cancer, colorectal carcinoma, cervical cancer, gastric carcinoma, kidney cancer, metastatic renal cell carcinoma, leukemia, ovarian cancer, and malignant glioma.

### Claim 84 (depends on 83)

The method of claim 83, wherein the cancer is selected from the group consisting of: metastatic melanoma, metastatic prostate cancer, and metastatic breast cancer.
